查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1535851

曲菌病治疗市场- 依类型（急性、慢性曲菌病）、药物类别（抗霉菌药物[唑类、棘白菌素类、多烯类]、皮质类固醇[泼尼松龙、泼尼松]）、药物形式、配销通路- 全球预测 (2024 - 2032)

Aspergillosis Treatment Market - By Type (Acute, Chronic Aspergillosis), Drug Class (Antifungal Drugs [Azoles, Echinocandins, Polyenes], Corticosteroids [Prednisolone, Prednisone]), Drug Form, Distribution Channel - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 231 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于免疫功能低下个体（如接受化疗、器官移植或爱滋病毒/爱滋病感染者）曲霉菌感染增加，预计 2024 年至 2032 年曲霉病治疗市场复合年增长率将达到 4.3%。据 CDC 称，大约 1-2% 的器官移植受者患有曲霉菌病。此外，气喘和慢性阻塞性肺病等呼吸系统疾病的盛行率不断上升，分别影响超过 2,500 万和 1,600 万美国人。由于免疫系统减弱，人口老化更容易受到感染，这进一步增加了对曲菌病治疗的需求。

新抗真菌药物的开发和诊断技术的改进提高了治疗效果和准确性。对真菌感染研究的认识和资助的提高导致了更好的治疗方案和更强大的医疗基础设施。不断增长的医疗保健投资，特别是在新兴经济体，预计将进一步推动市场，确保更广泛地获得先进治疗并改善患者的治疗效果。

整个曲菌病治疗产业根据类型、药物类别、药物剂型、配销通路和地区进行分类。

由于皮质类固醇类药物在控制与感染相关的发炎反应方面的有效性，它有望在 2032 年之前获得巨大的关注。皮质类固醇，如泼尼松和甲基泼尼松龙，通常用于减少过敏性支气管肺曲菌病 (ABPA) 和慢性肺曲菌病 (CPA) 患者的发炎和免疫反应。这些药物有助于缓解喘息、气喘和胸闷等症状，显着缓解患者的症状。呼吸系统疾病盛行率的增加和曲菌病发生率的上升正在推动对皮质类固醇的需求。

到 2032 年，注射剂细分市场将占据显着的市场份额，因为它在药物输送和功效方面具有优势。注射製剂因其能够将高剂量的药物直接输送到血液中而受到青睐，从而确保更快、更有效地治疗严重或全身性曲霉菌感染。这种给药途径对于患有严重真菌感染的患者或因胃肠道问题或吸收问题而无法耐受口服药物的患者至关重要。人们越来越重视快速有效的治疗方案，加上註射药物配方的进步，正在推动该细分市场的成长。

受真菌感染高盛行率、先进的医疗基础设施和大量研究投资的推动，到 2032 年，北美曲霉菌病治疗市场规模将快速扩大。该地区完善的医疗保健系统和强大的医学研究能力促进了创新治疗方案的开发和采用。此外，慢性呼吸道疾病和免疫功能低下疾病的发生率不断上升，导致对有效曲菌病治疗的需求增加。旨在改善医疗保健效果的政府措施和资金进一步促进了整个地区的市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 曲霉菌病发生率上升
      • 人们对真菌感染的认识不断增强
      • 新型抗真菌剂的开发
    • 产业陷阱与挑战
      • 治疗选择有限
      • 治疗费用高
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 2023 年定价分析
    • 按地区
    • 按关键人物
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 急性曲菌病
  • 慢性曲菌病

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

  • 主要趋势
  • 抗真菌药物
    • 唑类
    • 棘白菌素
    • 多烯
    • 烯丙胺
    • 其他抗真菌药物
  • 皮质类固醇
    • 泼尼松龙
    • 强的松
    • 甲基强的松龙
    • 其他皮质类固醇
  • 其他药品类

第 7 章：市场估计与预测：按药物剂型，2021 - 2032 年

  • 主要趋势
  • 口服
    • 平板电脑
    • 胶囊
  • 注射
  • 药膏
  • 粉末

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Astra Zeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Endo International plc
  • F2G
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mayne Pharma Group Limited
  • Novartis AG
  • PULMATRiX, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Viatris Inc.
简介目录
Product Code: 9917

Aspergillosis treatment market is anticipated to record 4.3% CAGR over 2024-2032, driven by a rise in Aspergillosis infections among immunocompromised individuals, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. According to the CDC, about 1-2% of organ transplant recipients develop Aspergillosis. Additionally, there is increasing prevalence of respiratory conditions like asthma and COPD, which affect over 25 million and 16 million Americans respectively. The aging population, more susceptible to infections due to weakened immune systems, further boosts demand for Aspergillosis treatments.

The development of new antifungal agents and improved diagnostic techniques has enhanced treatment efficacy and accuracy. Increased awareness and funding for fungal infection research have led to better treatment protocols and stronger healthcare infrastructure. Growing healthcare investments, particularly in emerging economies, are expected to further drive the market, ensuring wider access to advanced treatments and improving patient outcomes.

The overall Aspergillosis treatment industry is classified based on type, drug class, drug form, distribution channel, and region.

The corticosteroids drug class segment is poised to gain substantial traction through 2032 due to its effectiveness in managing inflammatory responses associated with the infection. Corticosteroids, such as prednisone and methylprednisolone, are commonly used to reduce inflammation and immune responses in patients with allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA). These drugs help alleviate symptoms such as wheezing, shortness of breath, and chest tightness, providing significant relief to patients. The increasing prevalence of respiratory conditions and the rising incidence of Aspergillosis are driving the demand for corticosteroids.

The injections segment will hold a notable market share by 2032, owing to the advantages it offers in terms of drug delivery and efficacy. Injectable formulations are preferred for their ability to deliver high doses of medication directly into the bloodstream, ensuring faster and more effective treatment of severe or systemic Aspergillosis infections. This route of administration is crucial for patients with severe fungal infections or those who cannot tolerate oral medications due to gastrointestinal issues or absorption problems. The growing emphasis on rapid and effective treatment options, coupled with advancements in injectable drug formulations, is driving the segment growth.

North American Aspergillosis treatment market size will expand at a rapid pace through 2032, driven by high prevalence rate of fungal infections, advanced healthcare infrastructure, and substantial research investments. The region's well-established healthcare systems and significant medical research capabilities facilitate the development and adoption of innovative treatment options. Additionally, the rising incidence of chronic respiratory diseases and immunocompromised conditions contributes to the increased demand for effective Aspergillosis therapies. Government initiatives and funding aimed at improving healthcare outcomes further bolster market growth across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of aspergillosis
      • 3.2.1.2 Growing awareness of fungal infections
      • 3.2.1.3 Development of new antifungal agents
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Limited treatment options
      • 3.2.2.2 High treatment costs
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Pricing analysis, 2023
    • 3.6.1 By region
    • 3.6.2 By key player
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Acute aspergillosis
  • 5.3 Chronic aspergillosis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Antifungal drugs
    • 6.2.1 Azoles
    • 6.2.2 Echinocandins
    • 6.2.3 Polyenes
    • 6.2.4 Allylamines
    • 6.2.5 Other antifungal drugs
  • 6.3 Corticosteroids
    • 6.3.1 Prednisolone
    • 6.3.2 Prednisone
    • 6.3.3 Methylprednisolone
    • 6.3.4 Other corticosteroids
  • 6.4 Other drug class

Chapter 7 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
    • 7.2.1 Tablets
    • 7.2.2 Capsules
  • 7.3 Injections
  • 7.4 Ointments
  • 7.5 Powders

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Astellas Pharma Inc.
  • 10.3 Astra Zeneca PLC
  • 10.4 Basilea Pharmaceutica Ltd.
  • 10.5 Bayer AG
  • 10.6 Endo International plc
  • 10.7 F2G
  • 10.8 GSK plc
  • 10.9 Johnson & Johnson
  • 10.10 Merck & Co., Inc.
  • 10.11 Mayne Pharma Group Limited
  • 10.12 Novartis AG
  • 10.13 PULMATRiX, Inc.
  • 10.14 Takeda Pharmaceutical Company Ltd.
  • 10.15 Viatris Inc.